ReviewFrontiers in endocrinology2023
Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 14 citations in OpenAlex.
- Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile.Renal failure · 2026Article
- Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD).Diabetes, obesity & metabolism · 2026Observational
- Finerenone exposure and ischaemic stroke in patients with type 2 diabetes and chronic kidney disease: A propensity score-matched cohort study.Clinical medicine (London, England) · 2026Article
- Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis.Frontiers in medicine · 2026Article
- Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease.Frontiers in pharmacology · 2026Article
- Efficacy and safety of finerenone in chronic kidney disease stages 3-4 in diabetic and non-diabetic patients with an eGFR 20-60 mL/min: a prospective cohort study.Frontiers in nephrology · 2026Article
- Aldosterone in Chronic Kidney Disease.Biomedicines · 2025Review
- Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease.International journal of molecular sciences · 2025Review
- Prognostic value of microRNA-495-3p, adiponectin, and cardiometabolic index in type 2 diabetic nephropathy.World journal of diabetes · 2025Article
- Article
- Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study.Drug design, development and therapy · 2025Article
- Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease.Frontiers in nutrition · 2025Review
- Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects.Heart failure reviews · 2025Review
- GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?Life (Basel, Switzerland) · 2024Review
- Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases.Frontiers in endocrinology · 2024Article
- A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a common disorder with numerous severe clinical implications. Due to a high level of fibrosis and inflammation that contributes to renal and cardiovascular disease (CVD), existing treatments have not effectively mitigated residual risk for patients with DKD. Excess activation of mineralocorticoid receptors (MRs) plays a significant role in the progression of renal and CVD, mostly by stimulating fibrosis and inflammation. However, the application of traditional steroidal MR antagonists (MRAs) to DKD has been limited by adverse events. Finerenone (FIN), a third-generation non-steroidal selective MRA, has revealed anti-fibrotic and anti-inflammatory effects in pre-clinical studies. Current clinical trials, such as FIDELIO-DKD and FIGARO-DKD and their combined analysis FIDELITY, have elucidated that FIN reduces the kidney and CV composite outcomes and risk of hyperkalemia compared to traditional steroidal MRAs in patients with DKD. As a result, FIN should be regarded as one of the mainstays of treatment for patients with DKD. In this review, the safety, efficiency, and potential mechanisms of FIN treatment on the renal system in patients with DKD is reviewed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.